statistiche ricercatore

Continente	#
NA - Nord America	522
AS - Asia	351
EU - Europa	254
SA - Sud America	59
Continente sconosciuto - Info sul continente non disponibili	21
AF - Africa	14
Totale	1.221

Nazione	#
US - Stati Uniti d'America	503
CN - Cina	104
SG - Singapore	97
DE - Germania	59
VN - Vietnam	52
RU - Federazione Russa	48
HK - Hong Kong	47
BR - Brasile	43
IT - Italia	30
IE - Irlanda	28
FI - Finlandia	27
FR - Francia	14
GB - Regno Unito	13
CA - Canada	12
IN - India	12
ZA - Sudafrica	7
AR - Argentina	6
PL - Polonia	6
SE - Svezia	6
AT - Austria	5
BD - Bangladesh	5
BE - Belgio	5
CO - Colombia	4
ES - Italia	4
JP - Giappone	4
MX - Messico	4
TR - Turchia	4
AZ - Azerbaigian	3
CH - Svizzera	3
EC - Ecuador	3
JO - Giordania	3
KR - Corea	3
EG - Egitto	2
ID - Indonesia	2
IQ - Iraq	2
IR - Iran	2
MA - Marocco	2
PH - Filippine	2
PK - Pakistan	2
SK - Slovacchia (Repubblica Slovacca)	2
AE - Emirati Arabi Uniti	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
GE - Georgia	1
HN - Honduras	1
HU - Ungheria	1
IL - Israele	1
JM - Giamaica	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LV - Lettonia	1
MY - Malesia	1
NI - Nicaragua	1
NL - Olanda	1
PE - Perù	1
RO - Romania	1
SC - Seychelles	1
UZ - Uzbekistan	1
VE - Venezuela	1
ZW - Zimbabwe	1
Totale	1.201

Nome	#
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms	160
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin	140
Genomic profiling and genotype-phenotype correlations in myeloproliferative neoplasms	124
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis	114
COVID-19 in Patients with Hematologic Diseases	100
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms	98
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms	98
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms	97
Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms	80
Isolated congenital asplenia: An overlooked cause of thrombocytosis	76
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients	67
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms	67
Totale	1.221

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	13	0	0	0	0	0	0	1	0	1	1	3	7
2022/2023	74	8	4	1	8	5	5	0	0	24	0	17	2
2023/2024	149	16	14	8	5	15	59	7	12	3	3	3	4
2024/2025	294	17	17	1	3	1	17	20	22	74	20	39	63
2025/2026	510	44	39	56	48	68	13	97	20	67	27	23	8
2026/2027	137	14	39	29	55	0	0	0	0	0	0	0	0
Totale													1.221